Neoplasm, Residual [clinicaltrials_resource:2db9b28cf5804078c14bd2466017c000]
condition [clinicaltrials_vocabulary:condition]
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow [clinicaltrials:NCT00172068]WT1 for the Detection of Minimal Residual Disease [clinicaltrials:NCT00179829]Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath [clinicaltrials:NCT00199030]clinicaltrials:NCT00267085Treatment of Adult ALL With an MRD-directed Programme. [clinicaltrials:NCT00358072]Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission [clinicaltrials:NCT00458523]clinicaltrials:NCT00560794Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia [clinicaltrials:NCT00795756]Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease [clinicaltrials:NCT00819143]Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease [clinicaltrials:NCT00863434]clinicaltrials:NCT00923013T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis [clinicaltrials:NCT01078337]clinicaltrials:NCT01158885clinicaltrials:NCT01207388First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade [clinicaltrials:NCT01215344]clinicaltrials:NCT01258933Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS) [clinicaltrials:NCT01311258]Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia [clinicaltrials:NCT01347996]clinicaltrials:NCT01392170clinicaltrials:NCT01460498Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia [clinicaltrials:NCT01533168]Fractionated Radiosurgery for Painful Spinal Metastases [clinicaltrials:NCT01594892]Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial [clinicaltrials:NCT01629745]clinicaltrials:NCT01665001clinicaltrials:NCT01677949Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) [clinicaltrials:NCT01723657]clinicaltrials:NCT01751425Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) [clinicaltrials:NCT01770158]Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [clinicaltrials:NCT01784068]clinicaltrials:NCT01883219Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [clinicaltrials:NCT01894477]clinicaltrials:NCT02067143clinicaltrials:NCT02169609Interferon α for the Therapy of Minimal Residual Disease [clinicaltrials:NCT02185261]Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT02185781]SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission [clinicaltrials:NCT02270463]Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy [clinicaltrials:NCT02275533]clinicaltrials:NCT02314871Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation [clinicaltrials:NCT02338050]clinicaltrials:NCT02339805
condition browse [clinicaltrials_vocabulary:condition-browse]
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow [clinicaltrials:NCT00172068]WT1 for the Detection of Minimal Residual Disease [clinicaltrials:NCT00179829]Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath [clinicaltrials:NCT00199030]clinicaltrials:NCT00267085Treatment of Adult ALL With an MRD-directed Programme. [clinicaltrials:NCT00358072]Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission [clinicaltrials:NCT00458523]clinicaltrials:NCT00560794Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia [clinicaltrials:NCT00795756]Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease [clinicaltrials:NCT00819143]Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease [clinicaltrials:NCT00863434]clinicaltrials:NCT00923013T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis [clinicaltrials:NCT01078337]clinicaltrials:NCT01158885clinicaltrials:NCT01207388First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade [clinicaltrials:NCT01215344]clinicaltrials:NCT01258933Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS) [clinicaltrials:NCT01311258]Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia [clinicaltrials:NCT01347996]clinicaltrials:NCT01392170clinicaltrials:NCT01460498Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia [clinicaltrials:NCT01533168]Fractionated Radiosurgery for Painful Spinal Metastases [clinicaltrials:NCT01594892]Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial [clinicaltrials:NCT01629745]clinicaltrials:NCT01665001clinicaltrials:NCT01677949Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) [clinicaltrials:NCT01723657]clinicaltrials:NCT01751425Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) [clinicaltrials:NCT01770158]Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [clinicaltrials:NCT01784068]clinicaltrials:NCT01883219Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [clinicaltrials:NCT01894477]clinicaltrials:NCT02067143clinicaltrials:NCT02169609Interferon α for the Therapy of Minimal Residual Disease [clinicaltrials:NCT02185261]Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT02185781]SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission [clinicaltrials:NCT02270463]Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy [clinicaltrials:NCT02275533]clinicaltrials:NCT02314871Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation [clinicaltrials:NCT02338050]clinicaltrials:NCT02339805
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Neoplasm, Residual [clinicaltrials_resource:2db9b28cf5804078c14bd2466017c000]
Bio2RDF identifier
2db9b28cf5804078c14bd2466017c000
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2db9b28cf5804078c14bd2466017c000
identifier
clinicaltrials_resource:2db9b28cf5804078c14bd2466017c000
title
Neoplasm, Residual
@en
type
label
Neoplasm, Residual [clinicaltrials_resource:2db9b28cf5804078c14bd2466017c000]
@en
Neoplasm, Residual